Management of Gallbladder Cancer Complicated by Mirizzi Syndrome

Critical Initial Assessment

High-quality cross-sectional imaging (CT/MRI) is mandatory to evaluate tumor penetration, direct organ invasion, vascular involvement, and nodal/distant metastases in patients with gallbladder cancer complicated by Mirizzi syndrome 1
Staging laparoscopy is recommended before laparotomy to identify occult peritoneal or hepatic metastases (present in 10-20% at presentation) and avoid unnecessary laparotomy in patients with gallbladder cancer complicated by Mirizzi syndrome 1, 2

Extended cholecystectomy is mandatory for resectable disease, which includes en bloc resection of gallbladder with wedge resection of liver segments IVb and V (minimum) to achieve R0 margins in patients with gallbladder cancer complicated by Mirizzi syndrome 2
Regional lymphadenectomy including porta hepatis, gastrohepatic ligament, and retroduodenal regions is necessary for resectable disease in patients with gallbladder cancer complicated by Mirizzi syndrome 1
Bile duct resection should only be performed when necessary to achieve negative margins, not routinely, in patients with gallbladder cancer complicated by Mirizzi syndrome 1

Gemcitabine plus cisplatin is the standard first-line chemotherapy regimen for advanced disease, providing approximately 4 months survival benefit in patients with unresectable gallbladder cancer complicated by Mirizzi syndrome 2, 3
Biliary stenting via ERCP is used for symptomatic obstruction, with metal stents preferred if life expectancy exceeds 6 months in patients with unresectable gallbladder cancer complicated by Mirizzi syndrome 1, 2

Adjuvant gemcitabine plus cisplatin chemotherapy may be considered for high-risk patients after R0 resection in patients with gallbladder cancer complicated by Mirizzi syndrome 2
Observation alone is acceptable after R0 resection with negative nodes in patients with gallbladder cancer complicated by Mirizzi syndrome 1

R0 resection status is the most important predictor of survival in patients with gallbladder cancer complicated by Mirizzi syndrome 1, 2
Five-year survival rates by stage are 60% (stage 0), 39% (stage I), 15% (stage II), 5% (stage III), 1% (stage IV) in patients with gallbladder cancer complicated by Mirizzi syndrome 1
Median survival for stage IV disease is 5.8 months, emphasizing importance of early palliative chemotherapy in patients with unresectable gallbladder cancer complicated by Mirizzi syndrome 1